Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

AccesswireFeb 24 08:00 ET

Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication

TipRanksFeb 20 11:39 ET

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

AccesswireFeb 20 08:00 ET

Lexaria Bioscience Granted Two New DehydraTECH Patents

TipRanksFeb 11 09:30 ET

Express News | Lexaria Granted Two US Patents For The Use Of DehydraTECH In Epilepsy Treatment

BenzingaFeb 11 08:22 ET

Express News | Lexaria Bioscience Corp. Begins Dosing In DehydraTECH GLP-1 Rodent Distribution Study

BenzingaFeb 6 09:47 ET

Express News | Lexaria Completes Submission To HREC For Planned Additional Of Study Arm 5 To Evaluate DehydraTECH-Tirzepatide Formulation

BenzingaFeb 5 09:17 ET

Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024

TipRanksJan 30 11:09 ET

Lexaria Unveils 2025 R&D Plans Focused On GLP-1: To Finalize Human Pilot Study #3, Launch Phase 1b Study In Australia, Complete Human Pilot Study #5, Conduct Fluorescent Biodistribution Study, And Run Additional Animal Studies

BenzingaJan 30 09:18 ET

Lexaria Releases Annual Letter From the CEO

AccesswireJan 30 09:15 ET

Lexaria Bioscience Is Maintained at Buy by HC Wainwright & Co.

Dow JonesJan 24 07:26 ET · Ratings

Lexaria Bioscience Analyst Ratings

BenzingaJan 24 07:14 ET · Ratings

H.C. Wainwright Maintains Lexaria Bioscience(LEXX.US) With Buy Rating, Cuts Target Price to $7

Moomoo NewsJan 24 06:31 ET · Ratings

Lexaria Bioscience Price Target Lowered to $7 From $10 at H.C. Wainwright

TipRanksJan 24 06:10 ET

Express News | Lexaria Bioscience Corp Files for Mixed Shelf of up to $50 Mln - SEC Filing

ReutersJan 22 16:07 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaJan 15 16:06 ET

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

AccesswireJan 15 09:20 ET

Lexaria Bioscience Shares Are Trading Lower. The Company Announced Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings From Human Study GLP-1-H24-3.

BenzingaJan 14 12:07 ET

Express News | Lexaria Bioscience Shares Are Trading Lower. The Company Announced Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings From Human Study GLP-1-H24-3

BenzingaJan 14 12:07 ET

Lexaria Bioscience Says Oral DehydraTECH-Tirzepatide Causes Fewer Adverse Effects

MT NewswiresJan 14 09:59 ET